Ginkgo Bioworks reported mixed Q3 results, with a $45 million one-time revenue boost masking underlying revenue growth issues ...

Return on Assets (ROA): Ginkgo Bioworks Holdings's ROA lags behind industry averages, suggesting challenges in maximizing ...

One of the few bright spots in Boston’s life-science lab space market this year has dimmed.

Boston-based Ginkgo Bioworks has canceled plans to move into a 250K SF lab data center and will exit two Cambridge locations ...

View Ginkgo Bioworks Holdings, Inc. (DNA) current and estimated P/E ratio data provided by Seeking Alpha.

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) ...

As per analysts' assessments, Ginkgo Bioworks Holdings is favoring an Buy trajectory ... As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 10.37%. This indicates a ...

Analyst Tejas Savant of Morgan Stanley maintained a Hold rating on Pacific Biosciences (PACB – Research Report), retaining the price ...

The growth rate of an investment shows how much its value increases over time, helping to evaluate performance. A common way to calculate this is by using the compound annual growth rate (CAGR ...

BOSTON, Nov. 12, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the completion of the first milestone of ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...